Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
176 | Publisher: Radiant Insights Inc.
Industry: Medical Devices | Report Format: Electronic (PDF)
This market insight report on IV (Intravenous) Solutions is analyzed by Type and Nutrients for each of the geographic regions-North America, Europe, Asia-Pacific and Rest of World. The global IV Solutions market segments includes by Type- Partial Parenteral Nutrition (PPN) & Total Parenteral Nutrition (TPN); by Nutrients-Carbohydrates, Salt and Electrolytes, Minerals and Vitamins and Amino Acids. Estimations and predictions for the total global IV solutions market are given by geographic regions. Business profiles of 16 major companies are discussed in the report. The report covers more than 50 companies that are engaged in IV Solutions and related products. Major Contract Research Organizations serving IV Solution market are also covered in the Corporate Directory section of this report. Information related to product developments, partnerships, collaborations, and mergers and acquisitions is also included in the report. A total of 110 exclusive graphically represented exhibits complement the text.
1. SCOPE AND METHODOLOGY 1 2. REPORT SYNOPSIS 3 2.1 Introduction 3 History 3 Definitions 4 Intravenous 4 Intravenous Infusions 4 Parenteral 4 Enteral 4 Home Parenteral Nutrition (HPN) 4 Partial Parenteral Nutrition (PPN) 5 Total Parenteral Nutrition (TPN) 5 Benefits 5 Hazards of Intravenous Feeding 5 2.2 Segmentation of Intravenous Solutions 5 Exhibit 1. Segmentation of Intravenous Solutions Market by Type and Nutrients 5 2.2 Intravenous Solutions - Global Market Analysis 6 Exhibit 2. Intravenous Solutions - Global Historic Market (2000-2010) in US$ Billion 6 Exhibit 3. Intravenous Solutions - Global Market Estimations & Predictions (2011 - 2020) in US$ Billion 7 Exhibit 4. List of Major Global Companies in Intravenous Solutions Market 7 3. MARKET DYNAMICS 9 3.1 Market Overview 9 Economic Profile 9 Market Growth Factors 9 3.2 Global Intravenous Solutions Market 11 Exhibit 5. Intravenous Solutions - Global Historic Market (2000-2010) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 11 Exhibit 6. Intravenous Solutions - Global Market Shares (2005 & 2010) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 12 Exhibit 7. Intravenous Solutions - Global Market Estimations & Predictions (2011 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 13 Exhibit 8. Intravenous Solutions - Global Market Shares (2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 14 3.3 North America Intravenous Solutions Market 15 Exhibit 9. Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million 15 Exhibit 10. Intravenous Solutions – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada 16 3.3 (I) US Intravenous Solutions Market 16 3.3 (II) Canadian Intravenous Solutions Market 16 Exhibit 11. List of Major North American Intravenous Solutions Companies 16 3.4 European Intravenous Solutions Market 17 Exhibit 12. Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million 17 Exhibit 13. Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe 18 3.4 (I) German Intravenous Solutions Market 18 3.4 (II) French Intravenous Solutions Market 18 3.4 (III) UK Intravenous Solutions Market 18 3.4 (IV) Swiss Intravenous Solutions Market 18 3.4 (V) Russian Intravenous Solutions Market 19 Exhibit 14. List of Major European Intravenous Solutions Companies 19 3.5 Asia-Pacific Intravenous Solutions Market 20 Exhibit 15. Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 20 Exhibit 16. Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 21 3.5 (I) Japanese Intravenous Solutions Market 21 3.5 (II) Chinese Intravenous Solutions Market 21 3.5 (III) Indian Intravenous Solutions Market 21 3.5 (IV) Australian Intravenous Solutions Market 21 3.5 (V) South Korean Intravenous Solutions Market 21 Exhibit 17. List of Major Asia-Pacific Intravenous Solutions Companies 22 3.6 Rest of World Intravenous Solutions Market 23 Exhibit 18. Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, Israel, South African and Rest of World in US$ Million 23 Exhibit 19. Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, Israel, South African and Rest of World 24 3.6 (I) Brazilian Intravenous Solutions Market 24 3.6 (II) Israeli Intravenous Solutions Market 24 3.6 (III) South African Intravenous Solutions Market 24 3.7 Major Global Players in Intravenous Solutions Market 25 Ajinomoto Co., Inc. (Japan) 25 B. Braun Melsungen AG (Germany) 26 Baxter International, Inc. (USA) 28 Baxter (India) Pvt. Ltd. (India) 29 Claris Otsuka Private Ltd. (India) 30 Fresenius Kabi AG (Germany) 32 Hospira, Inc. (USA) 34 Kyowa Hakko Bio Co., Ltd. (Japan) 37 Laboratorios Grifols SA (Spain) 38 Liqvor Pharmaceuticals (Armenia) 40 Amanta Healthcare Ltd. (India) 43 Otsuka Pharmaceutical Co., Ltd. (Japan) 46 Sichuan Kelun Pharmaceutical Co., Ltd. (China) 46 Sino-Swed Pharmaceutical Corp., Ltd. (China) 47 Terumo Corporation (Japan) 48 3.8 Competition Analysis 50 Exhibit 20. Clinical Nutrition Market: 2012 Percentage Market Share of Major Companies 50 Exhibit 21. Intravenous Solution Products Market: 2013 Percentage Market Share of Major Companies 51 Exhibit 22. Companies in Intravenous Solutions Market – Annual Sales for 2006 through 2010 in US$ Million 51 Exhibit 23. Companies in Intravenous Solutions Market – Production Volume and Capacity in Unit/Tonnes/Liters 52 Exhibit 24. Solutions – Competitor Price Comparison 52 3.9 Major Activities in Intravenous Solutions Market 53 Baxter Plans to Build a New Intravenous Admixing Facility in Canada 53 Fresenius Kabi Launches Kabiven® in the US 53 Mallinckrodt Acquires Cadence Pharmaceuticals for US$ 1.4 Billion 54 Cardiome Acquires Correvio LLC 54 Grifols Enters into Agreement with Cumberland Pharmaceuticals to Market Ibuprofen for Intravenous Infusion 54 FDA Approves New Large-Volume Intravenous Containers of B. Braun Medical 55 Fresenius Kabi Forms JV for I.V. Generics 55 Sandoz Launches Authorized Generic Version of Argatroban Injection 55 BPC’s BIVIGAM™, a New Intravenous Immune Globulin Gains US FDA Approval 55 Hospira Recalls Electrolyte Solution 56 Otsuka, Mitsui and Claris Establish an IV Solutions Joint Venture Business in India 56 Kyowa Hakko Kirin Introduces the new NESP® INJECTION PLASTIC SYRINGE with Unified Injection Volume 56 Taiho Pharmaceutical Releases 5-HT3 Receptor Antagonist Aloxi® I.V. Infusion bag 0.75mg 57 Merck to Give Back Vernakalant’s Worldwide Marketing and Development Rights to Cardiome 57 Baxter Healthcare to Withdraw Automix Automated Nutrition Compounder Systems 57 Rienso® (ferumoxytol) Attains Marketing Authorization by EC for Iron Deficiency Anaemia Treatment in Adult Chronic Kidney Disease Patients 57 MTPC’s Label Extension for Remicade Facilitate in Shorter Infusion Time 58 Shionogi Gains Pediatric Use and Additional Indication Approvals for Purulent Meningities of Carbapenem-Type Antibiotic in Japan 58 Intravenous Solution Manufacturing Plant establishment in Sri Lanka 58 Hospira Introduces Imipenem-Cilastatin for injection, I.V in the US 59 Shionogi Introduces Carbapenem-type Antibiotic, Finibax® 0.5 g for Intravenous Drip Infusion 59 Baxter Acquires Baxa Corporation 59 Baxter Launches NUMETA, as the first Triple-Chamber IV Nutrition System for Premature Newborns and Children in Europe 60 FDA Grants 510(K) clearance to Introcan Safety® 3 Closed IV Catheter from B. Braun Medical 60 BD Introduces New Generation Short Peripheral IV Catheter 61 Mitisubishi Tanable Introduces Simponi Subcutaneous Injection 50mg Syringe 61 Benesis’ Venoglobulin IH 5% for Intravenous Injection Receives Approval for Additional Indication 61 Mitsubishi Tanabe Receives Approval for Partial Change in Dosage & Usage of Remicade for I.V. Infusion 100 62 OLIMEL, First Triple-Chamber Bag for Nutrition, Launched in Canada by Baxter 62 Daiichi Sankyo Launches Cravit® Intravenous Injections 63 Cadence Pharmaceuticals Launches OFIRMEV™ (acetaminophen) Injection, the First and Solitary Intravenous Formulation of Acetaminophen in the US 63 AmeriCares Enters into a Partnership Agreement with Baxter to offer Additional Lifesaving Intravenous Solutions to Haiti 63 Marck Biosciences Acquires Assets of Goa-based Ravish Infusion 64 Fresenius Medical Care and Galenica Establish Renal Pharmaceutical Company 64 Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV 64 Grifols Announces the Launch of FLEBOGAMMA® 10% DIF IVIG 65 Hospira Enters into New Contracts with Novation for Infusion Pumps, Solutions and Equipment 65 Venoglobulin®-IH 5% IV Approved for Additional Indications of Dermatomyositis and Polymyositis 66 GlaxoSmithKline and Genmab Alter Ofatumumab Development Program in Autoimmune Indications 66 BRINAVESS™ (vernakalant) IV for Infusion Granted Marketing Approval in the EU for Rapid Conversion of Recent Onset Atrial Fibrillation 66 Taiho Pharmaceutical to Launches Antineoplastic ABRAXANE® 66 Paracetamol IV in Plastic Pack 67 EMA Accepts MMA for FERAHEME® of AMAG Pharmaceuticals and Takeda; Global Registration Program for FERAHEME® to Treat Iron Deficiency Anemia Initiated 67 Grifols Acquires Talecris 67 CareFusion Concludes the Acquisition of Medegen 68 BioScrip Acquires Critical Homecare Solutions 68 RADICUT® BAG for IV Infusion 30mg, a New Dosage form of Cerebral Neuroprotectant RADICUT® injection 30 mg, Approved 68 Mitsubishi Tanabe Pharma Obtains Approval for New Indication of Psoriasis 69 Hospira Launches Environmental Friendly IV Containers 69 Evolva SA Completes Merger with Arpida Ltd 70 Claris Introduces Anti-infective Injectable Unit 70 Pfizer Completes Acquisition of Wyeth 70 Celldex Therapeutics Completes Acquisition of CuraGen Corporation 70 HYLENEX Commercially Launched by Baxter 71 Hospira Enters into New Agreements with MedAssets for IV Solutions, Renews Infusion Devices Agreement 71 Marck Biosciences Enters Singapore and Malaysia 71 Baxter and SIGMA in Exclusive Distribution Agreement for Infusion Pumps 72 Talecris Biotherapeutics Launches Gamunex Connexions Certificate Program 72 Gamunex® of Talecris Biotherapeutics Approved by the USFDA as Treatment for Neurological Disorder CIDP 73 Arpida Files New Drug Submission for Intravenous Iclaprim in Canada 73 Fresenius Medical Care Closes US License Agreement for Intravenous Iron Products 73 Antimicrobial IV Technology of Baxter Demonstrates Capability to Eliminate Six Pathogens Inclusive of MRSA and VRE 74 Hospira Enters into New Contracts with Premier Purchasing Partners for Infusion Devices, Solutions and Equipments 74 Arpida Files Marketing Authorization Application in Europe for Intravenous Iclaprim 75 Fresenius Medical Care Enters into Agreements for Intravenous Iron Products 75 Otsuka Pharmaceutical and PDL BioPharma Conclude Sale of IV Busulfex 75 Fresenius Kabi Expands Infusion Therapy Business in Latin America 75 Otsuka to Acquire Busulfex® IV from PDL BioPharma 76 Hospira Obtains Marketing Authorization in the EU for Retacrit™ 76 Voluven - Product for Prevention and Treatment of Severe Blood Volume Loss following Surgery – Approved by the FDA 76 New Safety Packaging Introduced by Baxter Healthcare for High Alert Drugs 76 Transition to NextGen IV Immunoglobulin- Flebogamma® DIF - Concluded in record time in the US by Grifols 77 Kyowa Hakko and Kirin Groups Formalize Strategic Alliance Agreement 77 Baxter in Joint Venture with Guangzhou Baiyunshan for Parenteral Nutritional Products in China 77 EMEA Authorizes NextGen IVIG Distribution in European Union 78 Kyowa Hakko Increases Amino Acid Prices in Europe 78 Shanghai Century Acquisition Corporation Acquires the Shares of Sichuan Kelun Pharmaceutical Co., Ltd 79 Advanced NutriSolutions Acquires Select Supplements from Kyowa Hakko 79 Mayne Pharma Acquisition Process Completed by Hospira 79 FDA issues Marketing License to Grifols for NextGen Intravenous Immunoglobulin (IVIG) in the US 79 Kyowa Hakko Releases White Paper Kit Attributed to Amino Acids and Related Compounds 79 Symbiq™ - The Next-Gen Infusion System from Hospira 80 Health Alliance of Greater Cincinnati to Replace its Entire Fleet of IV Pumps Across Seven Hospitals 80 Amigrand Intravenous Infusion Launched Jointly by Tanabe Seiyaku and Terumo 80 Systemic Fungal Infection Therapy AmBisome® 50 mg for Intravenous Drip Infusion - Launched 81 Kyowa Hakko Launches Lumistor™ 81 The First Significantly Advanced Flexible IV Container in 3 decades 81 A New Line of Intravenous Solutions – AVIVA from Baxter 82 Cadence Pharmaceuticals Acquires Rights to IV APAP 82 BioScrip Inc. Launches Specialty Infusion Operations on Western Coast by Acquiring Intravenous Therapy Services 82 Boniva® - The First Intravenous Medication to treat Postmenopausal Osteoporosis, Approved by the FDA 82 Ajinomoto Acquires Amoy Food Group from Groupe Danone 83 FLEXBUMIN- the Flexible Container Packaged Albumin Solution from Baxter, Approved 83 3.10 Analysis by Type 84 Exhibit 25. Intravenous Solutions by Type - Global Historic Market (2000-2010) for PPN and TPN in US$ Million 84 Exhibit 26. Intravenous Solutions by Type - Global Market Shares (2005 & 2010) for PPN and TPN 85 Exhibit 27. Intravenous Solutions by Type - Global Market Estimations & Predictions (2011 - 2020) for PPN and TPN in US$ Million 86 Exhibit 28. Intravenous Solutions by Type - Global Market Shares (2015 & 2020) for PPN and TPN 87 3.10.1 Partial Parenteral Nutrition 88 3.10.1.1 Global Market for Partial Parenteral Nutrition 88 Exhibit 29. Partial Parenteral Nutrition - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 89 Exhibit 30. Partial Parenteral Nutrition - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 90 3.10.1.2 North America Market for Partial Parenteral Nutrition 91 Exhibit 31. Partial Parenteral Nutrition - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 91 Exhibit 32. Partial Parenteral Nutrition - North American Market Shares (2010, 2015 & 2020) by Country US and Canada 92 3.10.1.2 (I) US Market for Partial Parenteral Nutrition 92 3.10.1.2 (II) Canadian Market for Partial Parenteral Nutrition 92 3.10.1.3 European Market for Partial Parenteral Nutrition 93 Exhibit 33. Partial Parenteral Nutrition - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 93 Exhibit 34. Partial Parenteral Nutrition - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 94 3.10.1.3 (I) German Market for Partial Parenteral Nutrition 94 3.10.1.3 (II) French Market for Partial Parenteral Nutrition 94 3.10.1.3 (III) UK Market for Partial Parenteral Nutrition 94 3.10.1.3 (IV) Swiss Market for Partial Parenteral Nutrition 94 3.10.1.3 (V) Russian Market for Partial Parenteral Nutrition 94 3.10.1.4 Asia-Pacific Market for Partial Parenteral Nutrition 95 Exhibit 35. Partial Parenteral Nutrition - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 95 Exhibit 36. Partial Parenteral Nutrition - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 96 3.10.1.4 (I) Japanese Market for Partial Parenteral Nutrition 96 3.10.1.4 (II) Chinese Market for Partial Parenteral Nutrition 96 3.10.1.4 (III) Indian Market for Partial Parenteral Nutrition 96 3.10.1.4 (IV) Australian Market for Partial Parenteral Nutrition 96 3.10.1.4 (V) South Korean Market for Partial Parenteral Nutrition 96 3.10.1.5 Rest of World Market for Partial Parenteral Nutrition 97 Exhibit 37. Partial Parenteral Nutrition - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 97 Exhibit 38. Partial Parenteral Nutrition - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 98 3.10.1.5 (II) Brazilian Market for Partial Parenteral Nutrition 98 3.10.1.5 (I) Israeli Market for Partial Parenteral Nutrition 98 3.10.1.5 (III) South African Market for Partial Parenteral Nutrition 98 3.10.2 Total Parenteral Nutrition 99 3.10.2.1 Global Market for Total Parenteral Nutrition 99 Exhibit 39. Total Parenteral Nutrition - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 99 Exhibit 40. Total Parenteral Nutrition - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 100 3.10.2.2 North American Market for Total Parenteral Nutrition 101 Exhibit 41. Total Parenteral Nutrition - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 101 Exhibit 42. Total Parenteral Nutrition - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 102 3.10.2.2 (I) US Market for Total Parenteral Nutrition 102 3.10.2.2 (II) Canadian Market for Total Parenteral Nutrition 102 3.10.2.3 European Market for Total Parenteral Nutrition 103 Exhibit 43. Total Parenteral Nutrition - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 103 Exhibit 44. Total Parenteral Nutrition - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 104 3.10.2.3 (I) German Market for Total Parenteral Nutrition 104 3.10.2.3 (II) French Market for Total Parenteral Nutrition 104 3.10.2.3 (III) UK Market for Total Parenteral Nutrition 104 3.10.2.3 (IV) Swiss Market for Total Parenteral Nutrition 104 3.10.2.3 (V) Russian Market for Total Parenteral Nutrition 104 3.10.2.4 Asia-Pacific Market for Total Parenteral Nutrition 105 Exhibit 45. Total Parenteral Nutrition - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 105 Exhibit 46. Total Parenteral Nutrition - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 106 3.10.2.4 (I) Japanese Market for Total Parenteral Nutrition 106 3.10.2.4 (II) Chinese Market for Total Parenteral Nutrition 106 3.10.2.4 (III) Indian Market for Total Parenteral Nutrition 106 3.10.2.4 (IV) Australian Market for Total Parenteral Nutrition 106 3.10.2.4 (V) South Korean Market for Total Parenteral Nutrition 106 3.10.2.5 Rest of World Market for Total Parenteral Nutrition 107 Exhibit 47. Total Parenteral Nutrition - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 107 Exhibit 48. Total Parenteral Nutrition - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 108 3.10.2.5 (II) Brazilian Market for Total Parenteral Nutrition 108 3.10.2.5 (I) Israeli Market for Total Parenteral Nutrition 108 3.10.2.5 (III) South African Market for Total Parenteral Nutrition 108 3.11 Analysis by Nutrients 109 Exhibit 49. Intravenous Solutions by Nutrients - Global Historic Market (2000-2010) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino Acids and Other in US$ Million 109 Exhibit 50. Intravenous Solutions by Nutrients - Global Market Shares (2005 & 2010) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino Acids and Other 110 Exhibit 51. Intravenous Solutions by Nutrients - Global Market Estimations & Predictions (2011 - 2020) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino-Acids and Other in US$ Million 111 Exhibit 52. Intravenous Solutions by Nutrients - Global Market Shares (2015 & 2020) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino-Acids and Other 112 3.11.1 Carbohydrates 113 3.11.1.1 Global Carbohydrate based Intravenous Solutions Market 113 Exhibit 53. Carbohydrate based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 113 Exhibit 54. Carbohydrate based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific, Japan and Rest of World 114 3.11.1.2 North American Carbohydrate based Intravenous Solutions Market 115 Exhibit 55. Carbohydrate based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 115 Exhibit 56. Carbohydrate based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 116 3.11.1.2 (I) US Carbohydrate based Intravenous Solutions Market 116 3.11.1.2 (II) Canadian Carbohydrate based Intravenous Solutions Market 116 3.11.1.3 European Carbohydrate based Intravenous Solutions Market 117 Exhibit 57. Carbohydrate based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 117 Exhibit 58. Carbohydrate based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 118 3.11.1.3 (I) German Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (II) French Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (III) UK Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (IV) Swiss Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (V) Russian Carbohydrate based Intravenous Solutions Market 118 3.11.1.4 Asia-Pacific Carbohydrate based Intravenous Solutions Market 119 Exhibit 59. Carbohydrate based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 119 Exhibit 60. Carbohydrate based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 120 3.11.1.4 (I) Japanese Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (II) Chinese Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (III) Indian Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (IV) Australian Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (V) South Korean Carbohydrate based Intravenous Solutions Market 120 3.11.1.5 Rest of World Carbohydrate based Intravenous Solutions Market 121 Exhibit 61. Carbohydrate based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 121 Exhibit 62. Carbohydrate based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 122 3.11.1.5 (II) Brazilian Carbohydrate based Intravenous Solutions Market 122 3.11.1.5 (I) Israeli Carbohydrate based Intravenous Solutions Market 122 3.11.1.5 (III) South African Carbohydrate based Intravenous Solutions Market 122 3.11.2 Salt and Electrolyte 123 3.11.2.1 Global Salt and Electrolyte based Intravenous Solutions Market 123 Exhibit 63. Salt and Electrolytes Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 124 Exhibit 64. Salt and Electrolytes Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe ,Asia-Pacific and Rest of World 125 3.11.2.2 North America Salt and Electrolyte based Intravenous Solutions Market 126 Exhibit 65. Salt and Electrolyte based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 126 Exhibit 66. Salt and Electrolyte based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 127 3.11.2.2 (I) US Salt and Electrolyte based Intravenous Solutions Market 127 3.11.2.2 (II) Canadian Salt and Electrolyte based Intravenous Solutions Market 127 3.11.2.3 European Salt and Electrolyte based Intravenous Solutions Market 128 Exhibit 67. Salt and Electrolyte based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 128 Exhibit 68. Salt and Electrolyte based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 129 3.11.2.3 (I) German Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (II) French Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (III) UK Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (IV) Swiss Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (V) Russian Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.4 Asia-Pacific Salt and Electrolyte based Intravenous Solutions Market 130 Exhibit 69. Salt and Electrolyte based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 130 Exhibit 70. Salt and Electrolyte based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 131 3.11.2.4 (I) Japanese Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (II) Chinese Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (III) Indian Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (IV) Australian Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (V) South Korean Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.5 Rest of World Salt and Electrolyte based Intravenous Solutions Market 132 Exhibit 71. Salt and Electrolyte based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 132 Exhibit 72. Salt and Electrolyte based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 133 3.11.2.5 (II) Brazilian Salt and Electrolyte based Intravenous Solutions Market 133 3.11.2.5 (I) Israeli Salt and Electrolyte based Intravenous Solutions Market 133 3.11.2.5 (III) South African Salt and Electrolyte based Intravenous Solutions Market 133 3.11.3 Mineral and Vitamin 134 3.11.3.1 Global Mineral and Vitamin based Intravenous Solutions Market 134 Exhibit 73. Mineral and Vitamin based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 134 Exhibit 74. Mineral and Vitamin based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 135 3.11.3.2 North America Mineral and Vitamin based Intravenous Solutions Market 136 Exhibit 75. Mineral and Vitamin based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 136 Exhibit 76. Mineral and Vitamin based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 137 3.11.3.2 (I) US Mineral and Vitamin based Intravenous Solutions Market 137 3.11.3.2 (II) Canadian Mineral and Vitamin based Intravenous Solutions Market 137 3.11.3.3 European Mineral and Vitamin based Intravenous Solutions Market 138 Exhibit 77. Mineral and Vitamin based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 138 Exhibit 78. Mineral and Vitamin based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 139 3.11.3.3 (I) German Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (II) French Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (III) UK Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (IV) Swiss Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (V) Russian Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.4 Asia-Pacific Mineral and Vitamin based Intravenous Solutions Market 140 Exhibit 79. Mineral and Vitamin based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 140 Exhibit 80. Mineral and Vitamin based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 141 3.11.3.4 (I) Japanese Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (II) Chinese Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (III) Indian Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (IV) Australian Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (V) South Korean Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.5 Rest of World Mineral and Vitamin based Intravenous Solutions Market 142 Exhibit 81. Mineral and Vitamin based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 142 Exhibit 82. Mineral and Vitamin based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 143 3.11.3.5 (II) Brazilian Mineral and Vitamin based Intravenous Solutions Market 143 3.11.3.5 (I) Israeli Mineral and Vitamin based Intravenous Solutions Market 143 3.11.3.5 (III) South African Mineral and Vitamin based Intravenous Solutions Market 143 3.11.4 Amino-Acid 144 3.11.4.1 Global Amino-Acid based Intravenous Solutions Market 144 Exhibit 83. Amino-Acid based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 145 Exhibit 84. Amino-Acid based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 146 3.11.4.2 North America Amino-Acid based Intravenous Solutions Market 147 Exhibit 85. Amino-Acid based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 147 Exhibit 86. Amino-Acid based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 148 3.11.4.2 (I) US Amino-Acid based Intravenous Solutions Market 148 3.11.4.2 (II) Canadian Amino-Acid based Intravenous Solutions Market 148 3.11.4.3 European Amino-Acid based Intravenous Solutions Market 149 Exhibit 87. Amino-Acid based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, UK, Switzerland, Russia and Rest of Europe in US$ Million 149 Exhibit 88. Amino-Acid based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 150 3.11.4.3 (I) German Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (II) French Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (III) UK Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (IV) Swiss Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (V) Russian Amino-Acid based Intravenous Solutions Market 150 3.11.4.4 Asia-Pacific Amino-Acid based Intravenous Solutions Market 151 Exhibit 89. Amino-Acid based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 151 Exhibit 90. Amino-Acid based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 152 3.11.4.4 (I) Japanese Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (II) Chinese Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (III) Indian Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (IV) Australian Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (V) South Korean Amino-Acid based Intravenous Solutions Market 152 3.11.4.5 Rest of World Amino-Acid based Intravenous Solutions Market 153 Exhibit 91. Amino-Acid based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 153 Exhibit 92. Amino-Acid based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 154 3.11.4.5 (II) Brazilian Amino-Acid based Intravenous Solutions Market 154 3.11.4.5 (I) Israeli Amino-Acid based Intravenous Solutions Market 154 3.11.4.5 (III) South African Amino-Acid based Intravenous Solutions Market 154 3.11.5 Other Nutrients 155 3.11.5.1 Global Other Nutrients based Intravenous Solutions Market 155 Exhibit 93. Other Nutrients based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 155 Exhibit 94. Other Nutrients based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 156 3.11.5.2 North America Other Nutrients based Intravenous Solutions Market 157 Exhibit 95. Other Nutrients based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 157 Exhibit 96. Other Nutrients based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 158 3.11.5.3 European Other Nutrients based Intravenous Solutions Market 159 Exhibit 97. Other Nutrients based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 159 Exhibit 98. Other Nutrients based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 160 3.11.5.4 Asia-Pacific Other Nutrients based Intravenous Solutions Market 161 Exhibit 99. Other Nutrients based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 161 Exhibit 100. Other Nutrients based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 162 3.11.5.5 Rest of World Other Nutrients based Intravenous Solutions Market 163 Exhibit 101. Other Nutrients based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 163 Exhibit 102. Other Nutrients based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 164 3.12 Intravenous Solutions – Market Outlook 165 4. PRODUCT TECHNOLOGY/RESEARCH 166 4.1 Introduction 166 Intravenous Solutions 166 Composition 166 Exhibit 103. Electrolyte Requirement 166 Exhibit 104. Contents for Common Fluids (mmol/litre) 167 Application 167 Exhibit 105. Fluid Requirements in Different Clinical Situations 168 Types of Intravenous Solutions 168 Large Volume Parenterals and Small Volume Parenterals 169 Exhibit 106. Fluid Comparison 169 Intravenous versus Oral Mode of Administration 170 Risks 171 Precautions 171 Fat Emulsions 171 Dextrose 172 Plasma Expanders 172 Cyclical Parenteral Nutrition (CPN) 172 Advantages of Cyclical PN Include 173 Exhibit 107. Global Consumption of Intravenous Solutions – 2013 Estimates 173 4.2 Segmentation of Intravenous Solutions 174 Segmentation by Type 174 Partial Parenteral Nutrition 174 Total Parenteral Nutrition 174 Complications 174 Complications due to Catheter Insertion 175 Metabolic Complications 175 Segmentation by Nutrients 175 Carbohydrates 175 Carbohydrates - Source of Nutrition 175 Introduction 175 Disadvantages of Over-feeding with the Carbon Source 176 Endogenous Glucose Production and Oxidation 177 Guidelines 177 Glucose/Fat Ratio 178 Salt and Elecrtolytes 178 Salt (Sodium chloride) and/or Other Electrolytes 178 Saline 178 Concentrations 179 Minerals and Vitamins 179 Minerals and Vitamins 179 Amino Acids 179 Amino Acids and/or Protein Hydrolysates 179 Dosage of Amino Acid Solutions for Intravenous Use 180 Other 181 Fat (lipid) Emulsions 181 Plasma Extenders 181 Exhibit 108. List of Agents Administered as IV Solutions or Additives 182 PACKAGING AND IDENTIFICATION LABELING OF APIs AND INTERMEDIATES 183 Source: FDA 183 General 183 Packaging Materials 183 Label Issuance and Control 183 Packaging and Labeling Operations 184 Storage and Distribution 184 Warehousing Procedures 184 Distribution Procedures 184 Specific Guidance for Apis Manufactured by Cell Culture/Fermentation 185 General 185 Cell Culture/Fermentation 186 Harvesting, Isolation and Purification 187 Viral Removal/Inactivation steps 187 Safety Assessment of Di (2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices 187 Safety Assessment of Di (2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices 188 Conclusions of the Safety Assessment 188 I V Infusion of Crystalloid Fluids and Drugs 188 Total Parenteral Nutrition (TPN) 188 Parenteral Nutrition 189 Government of India - Policy and Regulations on Drugs 189 Drug Regulation and Control: 189 Maharashtra FDA: Latest Reforms 190 Procedure for Drug Application in India 191 Import and Manufacturing Licenses and Approvals: 191 Labeling Requirements 191 Drug Price Regulation 192 History of Drug Price Regulation 192 Trends in Drug Price Control – India 193 Regulations on Patent Protection 194 Finale 195 A Summary of the Chinese Pharmaceutical Market 196 Consolidating the System – The State Drug Administration 196 Pharmaceutical Regulations 198 Pricing and Reimbursement 198 Pharmaceutical Classification 199 Registration 199 Clinical Investigation 202 Legal Reform: Intellectual Property Rights 204 Conclusion 205 Law of Drug Administration – China 205 Chapter I 205 General Provisions 205 Chapter II 205 Control over Drug Manufacturers 205 Chapter III 207 Control over Drug Distributors 207 Chapter V 208 Control over Drugs 208 Chapter VI 210 Control over Drug Packaging 210 Chapter VIII 211 Inspection of Drugs 211 Chapter X 212 Supplementary Provisions 212 Application of Knowledge and Skills Framework and its Review Procedure 213 Introduction 213 Decision to Form NHS KSF 213 Purpose of Skills Framework 213 Mode of Function 213 Overview 214 Distribution of Pharmaceutical Products: 215 4.3 Intravenous Solutions – Research Briefs 216 Intravenous Food Ingredients Leading to Liver Damage, Identified 216 International Dispute Regarding Intravenous Nutrition Administration May Have Been Resolved 216 Enteral Nutrition More Effective than TPN in Severe Acute Pancreatitis 217 Survival Period Post Hospital Discharge is Not Dependent on Intravenous Drug Administration 218 Intravenous Infusion Solution Ingredients Trigger Inflammation 218 Early Nasogastric-Enteral Nutrition for Managing Severe Acute Pancreatitis 219 V. CORPORATE DIRECTORY 220 VI. PATENTS INFORMATION 231
1. SCOPE AND METHODOLOGY 1 2. REPORT SYNOPSIS 3 2.1 Introduction 3 History 3 Definitions 4 Intravenous 4 Intravenous Infusions 4 Parenteral 4 Enteral 4 Home Parenteral Nutrition (HPN) 4 Partial Parenteral Nutrition (PPN) 5 Total Parenteral Nutrition (TPN) 5 Benefits 5 Hazards of Intravenous Feeding 5 2.2 Segmentation of Intravenous Solutions 5 Exhibit 1. Segmentation of Intravenous Solutions Market by Type and Nutrients 5 2.2 Intravenous Solutions - Global Market Analysis 6 Exhibit 2. Intravenous Solutions - Global Historic Market (2000-2010) in US$ Billion 6 Exhibit 3. Intravenous Solutions - Global Market Estimations & Predictions (2011 - 2020) in US$ Billion 7 Exhibit 4. List of Major Global Companies in Intravenous Solutions Market 7 3. MARKET DYNAMICS 9 3.1 Market Overview 9 Economic Profile 9 Market Growth Factors 9 3.2 Global Intravenous Solutions Market 11 Exhibit 5. Intravenous Solutions - Global Historic Market (2000-2010) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 11 Exhibit 6. Intravenous Solutions - Global Market Shares (2005 & 2010) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 12 Exhibit 7. Intravenous Solutions - Global Market Estimations & Predictions (2011 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 13 Exhibit 8. Intravenous Solutions - Global Market Shares (2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 14 3.3 North America Intravenous Solutions Market 15 Exhibit 9. Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million 15 Exhibit 10. Intravenous Solutions – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada 16 3.3 (I) US Intravenous Solutions Market 16 3.3 (II) Canadian Intravenous Solutions Market 16 Exhibit 11. List of Major North American Intravenous Solutions Companies 16 3.4 European Intravenous Solutions Market 17 Exhibit 12. Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million 17 Exhibit 13. Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe 18 3.4 (I) German Intravenous Solutions Market 18 3.4 (II) French Intravenous Solutions Market 18 3.4 (III) UK Intravenous Solutions Market 18 3.4 (IV) Swiss Intravenous Solutions Market 18 3.4 (V) Russian Intravenous Solutions Market 19 Exhibit 14. List of Major European Intravenous Solutions Companies 19 3.5 Asia-Pacific Intravenous Solutions Market 20 Exhibit 15. Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 20 Exhibit 16. Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 21 3.5 (I) Japanese Intravenous Solutions Market 21 3.5 (II) Chinese Intravenous Solutions Market 21 3.5 (III) Indian Intravenous Solutions Market 21 3.5 (IV) Australian Intravenous Solutions Market 21 3.5 (V) South Korean Intravenous Solutions Market 21 Exhibit 17. List of Major Asia-Pacific Intravenous Solutions Companies 22 3.6 Rest of World Intravenous Solutions Market 23 Exhibit 18. Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, Israel, South African and Rest of World in US$ Million 23 Exhibit 19. Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, Israel, South African and Rest of World 24 3.6 (I) Brazilian Intravenous Solutions Market 24 3.6 (II) Israeli Intravenous Solutions Market 24 3.6 (III) South African Intravenous Solutions Market 24 3.7 Major Global Players in Intravenous Solutions Market 25 Ajinomoto Co., Inc. (Japan) 25 B. Braun Melsungen AG (Germany) 26 Baxter International, Inc. (USA) 28 Baxter (India) Pvt. Ltd. (India) 29 Claris Otsuka Private Ltd. (India) 30 Fresenius Kabi AG (Germany) 32 Hospira, Inc. (USA) 34 Kyowa Hakko Bio Co., Ltd. (Japan) 37 Laboratorios Grifols SA (Spain) 38 Liqvor Pharmaceuticals (Armenia) 40 Amanta Healthcare Ltd. (India) 43 Otsuka Pharmaceutical Co., Ltd. (Japan) 46 Sichuan Kelun Pharmaceutical Co., Ltd. (China) 46 Sino-Swed Pharmaceutical Corp., Ltd. (China) 47 Terumo Corporation (Japan) 48 3.8 Competition Analysis 50 Exhibit 20. Clinical Nutrition Market: 2012 Percentage Market Share of Major Companies 50 Exhibit 21. Intravenous Solution Products Market: 2013 Percentage Market Share of Major Companies 51 Exhibit 22. Companies in Intravenous Solutions Market – Annual Sales for 2006 through 2010 in US$ Million 51 Exhibit 23. Companies in Intravenous Solutions Market – Production Volume and Capacity in Unit/Tonnes/Liters 52 Exhibit 24. Solutions – Competitor Price Comparison 52 3.9 Major Activities in Intravenous Solutions Market 53 Baxter Plans to Build a New Intravenous Admixing Facility in Canada 53 Fresenius Kabi Launches Kabiven® in the US 53 Mallinckrodt Acquires Cadence Pharmaceuticals for US$ 1.4 Billion 54 Cardiome Acquires Correvio LLC 54 Grifols Enters into Agreement with Cumberland Pharmaceuticals to Market Ibuprofen for Intravenous Infusion 54 FDA Approves New Large-Volume Intravenous Containers of B. Braun Medical 55 Fresenius Kabi Forms JV for I.V. Generics 55 Sandoz Launches Authorized Generic Version of Argatroban Injection 55 BPC’s BIVIGAM™, a New Intravenous Immune Globulin Gains US FDA Approval 55 Hospira Recalls Electrolyte Solution 56 Otsuka, Mitsui and Claris Establish an IV Solutions Joint Venture Business in India 56 Kyowa Hakko Kirin Introduces the new NESP® INJECTION PLASTIC SYRINGE with Unified Injection Volume 56 Taiho Pharmaceutical Releases 5-HT3 Receptor Antagonist Aloxi® I.V. Infusion bag 0.75mg 57 Merck to Give Back Vernakalant’s Worldwide Marketing and Development Rights to Cardiome 57 Baxter Healthcare to Withdraw Automix Automated Nutrition Compounder Systems 57 Rienso® (ferumoxytol) Attains Marketing Authorization by EC for Iron Deficiency Anaemia Treatment in Adult Chronic Kidney Disease Patients 57 MTPC’s Label Extension for Remicade Facilitate in Shorter Infusion Time 58 Shionogi Gains Pediatric Use and Additional Indication Approvals for Purulent Meningities of Carbapenem-Type Antibiotic in Japan 58 Intravenous Solution Manufacturing Plant establishment in Sri Lanka 58 Hospira Introduces Imipenem-Cilastatin for injection, I.V in the US 59 Shionogi Introduces Carbapenem-type Antibiotic, Finibax® 0.5 g for Intravenous Drip Infusion 59 Baxter Acquires Baxa Corporation 59 Baxter Launches NUMETA, as the first Triple-Chamber IV Nutrition System for Premature Newborns and Children in Europe 60 FDA Grants 510(K) clearance to Introcan Safety® 3 Closed IV Catheter from B. Braun Medical 60 BD Introduces New Generation Short Peripheral IV Catheter 61 Mitisubishi Tanable Introduces Simponi Subcutaneous Injection 50mg Syringe 61 Benesis’ Venoglobulin IH 5% for Intravenous Injection Receives Approval for Additional Indication 61 Mitsubishi Tanabe Receives Approval for Partial Change in Dosage & Usage of Remicade for I.V. Infusion 100 62 OLIMEL, First Triple-Chamber Bag for Nutrition, Launched in Canada by Baxter 62 Daiichi Sankyo Launches Cravit® Intravenous Injections 63 Cadence Pharmaceuticals Launches OFIRMEV™ (acetaminophen) Injection, the First and Solitary Intravenous Formulation of Acetaminophen in the US 63 AmeriCares Enters into a Partnership Agreement with Baxter to offer Additional Lifesaving Intravenous Solutions to Haiti 63 Marck Biosciences Acquires Assets of Goa-based Ravish Infusion 64 Fresenius Medical Care and Galenica Establish Renal Pharmaceutical Company 64 Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV 64 Grifols Announces the Launch of FLEBOGAMMA® 10% DIF IVIG 65 Hospira Enters into New Contracts with Novation for Infusion Pumps, Solutions and Equipment 65 Venoglobulin®-IH 5% IV Approved for Additional Indications of Dermatomyositis and Polymyositis 66 GlaxoSmithKline and Genmab Alter Ofatumumab Development Program in Autoimmune Indications 66 BRINAVESS™ (vernakalant) IV for Infusion Granted Marketing Approval in the EU for Rapid Conversion of Recent Onset Atrial Fibrillation 66 Taiho Pharmaceutical to Launches Antineoplastic ABRAXANE® 66 Paracetamol IV in Plastic Pack 67 EMA Accepts MMA for FERAHEME® of AMAG Pharmaceuticals and Takeda; Global Registration Program for FERAHEME® to Treat Iron Deficiency Anemia Initiated 67 Grifols Acquires Talecris 67 CareFusion Concludes the Acquisition of Medegen 68 BioScrip Acquires Critical Homecare Solutions 68 RADICUT® BAG for IV Infusion 30mg, a New Dosage form of Cerebral Neuroprotectant RADICUT® injection 30 mg, Approved 68 Mitsubishi Tanabe Pharma Obtains Approval for New Indication of Psoriasis 69 Hospira Launches Environmental Friendly IV Containers 69 Evolva SA Completes Merger with Arpida Ltd 70 Claris Introduces Anti-infective Injectable Unit 70 Pfizer Completes Acquisition of Wyeth 70 Celldex Therapeutics Completes Acquisition of CuraGen Corporation 70 HYLENEX Commercially Launched by Baxter 71 Hospira Enters into New Agreements with MedAssets for IV Solutions, Renews Infusion Devices Agreement 71 Marck Biosciences Enters Singapore and Malaysia 71 Baxter and SIGMA in Exclusive Distribution Agreement for Infusion Pumps 72 Talecris Biotherapeutics Launches Gamunex Connexions Certificate Program 72 Gamunex® of Talecris Biotherapeutics Approved by the USFDA as Treatment for Neurological Disorder CIDP 73 Arpida Files New Drug Submission for Intravenous Iclaprim in Canada 73 Fresenius Medical Care Closes US License Agreement for Intravenous Iron Products 73 Antimicrobial IV Technology of Baxter Demonstrates Capability to Eliminate Six Pathogens Inclusive of MRSA and VRE 74 Hospira Enters into New Contracts with Premier Purchasing Partners for Infusion Devices, Solutions and Equipments 74 Arpida Files Marketing Authorization Application in Europe for Intravenous Iclaprim 75 Fresenius Medical Care Enters into Agreements for Intravenous Iron Products 75 Otsuka Pharmaceutical and PDL BioPharma Conclude Sale of IV Busulfex 75 Fresenius Kabi Expands Infusion Therapy Business in Latin America 75 Otsuka to Acquire Busulfex® IV from PDL BioPharma 76 Hospira Obtains Marketing Authorization in the EU for Retacrit™ 76 Voluven - Product for Prevention and Treatment of Severe Blood Volume Loss following Surgery – Approved by the FDA 76 New Safety Packaging Introduced by Baxter Healthcare for High Alert Drugs 76 Transition to NextGen IV Immunoglobulin- Flebogamma® DIF - Concluded in record time in the US by Grifols 77 Kyowa Hakko and Kirin Groups Formalize Strategic Alliance Agreement 77 Baxter in Joint Venture with Guangzhou Baiyunshan for Parenteral Nutritional Products in China 77 EMEA Authorizes NextGen IVIG Distribution in European Union 78 Kyowa Hakko Increases Amino Acid Prices in Europe 78 Shanghai Century Acquisition Corporation Acquires the Shares of Sichuan Kelun Pharmaceutical Co., Ltd 79 Advanced NutriSolutions Acquires Select Supplements from Kyowa Hakko 79 Mayne Pharma Acquisition Process Completed by Hospira 79 FDA issues Marketing License to Grifols for NextGen Intravenous Immunoglobulin (IVIG) in the US 79 Kyowa Hakko Releases White Paper Kit Attributed to Amino Acids and Related Compounds 79 Symbiq™ - The Next-Gen Infusion System from Hospira 80 Health Alliance of Greater Cincinnati to Replace its Entire Fleet of IV Pumps Across Seven Hospitals 80 Amigrand Intravenous Infusion Launched Jointly by Tanabe Seiyaku and Terumo 80 Systemic Fungal Infection Therapy AmBisome® 50 mg for Intravenous Drip Infusion - Launched 81 Kyowa Hakko Launches Lumistor™ 81 The First Significantly Advanced Flexible IV Container in 3 decades 81 A New Line of Intravenous Solutions – AVIVA from Baxter 82 Cadence Pharmaceuticals Acquires Rights to IV APAP 82 BioScrip Inc. Launches Specialty Infusion Operations on Western Coast by Acquiring Intravenous Therapy Services 82 Boniva® - The First Intravenous Medication to treat Postmenopausal Osteoporosis, Approved by the FDA 82 Ajinomoto Acquires Amoy Food Group from Groupe Danone 83 FLEXBUMIN- the Flexible Container Packaged Albumin Solution from Baxter, Approved 83 3.10 Analysis by Type 84 Exhibit 25. Intravenous Solutions by Type - Global Historic Market (2000-2010) for PPN and TPN in US$ Million 84 Exhibit 26. Intravenous Solutions by Type - Global Market Shares (2005 & 2010) for PPN and TPN 85 Exhibit 27. Intravenous Solutions by Type - Global Market Estimations & Predictions (2011 - 2020) for PPN and TPN in US$ Million 86 Exhibit 28. Intravenous Solutions by Type - Global Market Shares (2015 & 2020) for PPN and TPN 87 3.10.1 Partial Parenteral Nutrition 88 3.10.1.1 Global Market for Partial Parenteral Nutrition 88 Exhibit 29. Partial Parenteral Nutrition - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 89 Exhibit 30. Partial Parenteral Nutrition - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 90 3.10.1.2 North America Market for Partial Parenteral Nutrition 91 Exhibit 31. Partial Parenteral Nutrition - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 91 Exhibit 32. Partial Parenteral Nutrition - North American Market Shares (2010, 2015 & 2020) by Country US and Canada 92 3.10.1.2 (I) US Market for Partial Parenteral Nutrition 92 3.10.1.2 (II) Canadian Market for Partial Parenteral Nutrition 92 3.10.1.3 European Market for Partial Parenteral Nutrition 93 Exhibit 33. Partial Parenteral Nutrition - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 93 Exhibit 34. Partial Parenteral Nutrition - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 94 3.10.1.3 (I) German Market for Partial Parenteral Nutrition 94 3.10.1.3 (II) French Market for Partial Parenteral Nutrition 94 3.10.1.3 (III) UK Market for Partial Parenteral Nutrition 94 3.10.1.3 (IV) Swiss Market for Partial Parenteral Nutrition 94 3.10.1.3 (V) Russian Market for Partial Parenteral Nutrition 94 3.10.1.4 Asia-Pacific Market for Partial Parenteral Nutrition 95 Exhibit 35. Partial Parenteral Nutrition - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 95 Exhibit 36. Partial Parenteral Nutrition - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 96 3.10.1.4 (I) Japanese Market for Partial Parenteral Nutrition 96 3.10.1.4 (II) Chinese Market for Partial Parenteral Nutrition 96 3.10.1.4 (III) Indian Market for Partial Parenteral Nutrition 96 3.10.1.4 (IV) Australian Market for Partial Parenteral Nutrition 96 3.10.1.4 (V) South Korean Market for Partial Parenteral Nutrition 96 3.10.1.5 Rest of World Market for Partial Parenteral Nutrition 97 Exhibit 37. Partial Parenteral Nutrition - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 97 Exhibit 38. Partial Parenteral Nutrition - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 98 3.10.1.5 (II) Brazilian Market for Partial Parenteral Nutrition 98 3.10.1.5 (I) Israeli Market for Partial Parenteral Nutrition 98 3.10.1.5 (III) South African Market for Partial Parenteral Nutrition 98 3.10.2 Total Parenteral Nutrition 99 3.10.2.1 Global Market for Total Parenteral Nutrition 99 Exhibit 39. Total Parenteral Nutrition - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 99 Exhibit 40. Total Parenteral Nutrition - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 100 3.10.2.2 North American Market for Total Parenteral Nutrition 101 Exhibit 41. Total Parenteral Nutrition - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 101 Exhibit 42. Total Parenteral Nutrition - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 102 3.10.2.2 (I) US Market for Total Parenteral Nutrition 102 3.10.2.2 (II) Canadian Market for Total Parenteral Nutrition 102 3.10.2.3 European Market for Total Parenteral Nutrition 103 Exhibit 43. Total Parenteral Nutrition - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 103 Exhibit 44. Total Parenteral Nutrition - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 104 3.10.2.3 (I) German Market for Total Parenteral Nutrition 104 3.10.2.3 (II) French Market for Total Parenteral Nutrition 104 3.10.2.3 (III) UK Market for Total Parenteral Nutrition 104 3.10.2.3 (IV) Swiss Market for Total Parenteral Nutrition 104 3.10.2.3 (V) Russian Market for Total Parenteral Nutrition 104 3.10.2.4 Asia-Pacific Market for Total Parenteral Nutrition 105 Exhibit 45. Total Parenteral Nutrition - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 105 Exhibit 46. Total Parenteral Nutrition - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 106 3.10.2.4 (I) Japanese Market for Total Parenteral Nutrition 106 3.10.2.4 (II) Chinese Market for Total Parenteral Nutrition 106 3.10.2.4 (III) Indian Market for Total Parenteral Nutrition 106 3.10.2.4 (IV) Australian Market for Total Parenteral Nutrition 106 3.10.2.4 (V) South Korean Market for Total Parenteral Nutrition 106 3.10.2.5 Rest of World Market for Total Parenteral Nutrition 107 Exhibit 47. Total Parenteral Nutrition - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 107 Exhibit 48. Total Parenteral Nutrition - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 108 3.10.2.5 (II) Brazilian Market for Total Parenteral Nutrition 108 3.10.2.5 (I) Israeli Market for Total Parenteral Nutrition 108 3.10.2.5 (III) South African Market for Total Parenteral Nutrition 108 3.11 Analysis by Nutrients 109 Exhibit 49. Intravenous Solutions by Nutrients - Global Historic Market (2000-2010) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino Acids and Other in US$ Million 109 Exhibit 50. Intravenous Solutions by Nutrients - Global Market Shares (2005 & 2010) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino Acids and Other 110 Exhibit 51. Intravenous Solutions by Nutrients - Global Market Estimations & Predictions (2011 - 2020) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino-Acids and Other in US$ Million 111 Exhibit 52. Intravenous Solutions by Nutrients - Global Market Shares (2015 & 2020) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino-Acids and Other 112 3.11.1 Carbohydrates 113 3.11.1.1 Global Carbohydrate based Intravenous Solutions Market 113 Exhibit 53. Carbohydrate based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 113 Exhibit 54. Carbohydrate based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific, Japan and Rest of World 114 3.11.1.2 North American Carbohydrate based Intravenous Solutions Market 115 Exhibit 55. Carbohydrate based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 115 Exhibit 56. Carbohydrate based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 116 3.11.1.2 (I) US Carbohydrate based Intravenous Solutions Market 116 3.11.1.2 (II) Canadian Carbohydrate based Intravenous Solutions Market 116 3.11.1.3 European Carbohydrate based Intravenous Solutions Market 117 Exhibit 57. Carbohydrate based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 117 Exhibit 58. Carbohydrate based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 118 3.11.1.3 (I) German Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (II) French Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (III) UK Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (IV) Swiss Carbohydrate based Intravenous Solutions Market 118 3.11.1.3 (V) Russian Carbohydrate based Intravenous Solutions Market 118 3.11.1.4 Asia-Pacific Carbohydrate based Intravenous Solutions Market 119 Exhibit 59. Carbohydrate based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 119 Exhibit 60. Carbohydrate based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 120 3.11.1.4 (I) Japanese Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (II) Chinese Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (III) Indian Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (IV) Australian Carbohydrate based Intravenous Solutions Market 120 3.11.1.4 (V) South Korean Carbohydrate based Intravenous Solutions Market 120 3.11.1.5 Rest of World Carbohydrate based Intravenous Solutions Market 121 Exhibit 61. Carbohydrate based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 121 Exhibit 62. Carbohydrate based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 122 3.11.1.5 (II) Brazilian Carbohydrate based Intravenous Solutions Market 122 3.11.1.5 (I) Israeli Carbohydrate based Intravenous Solutions Market 122 3.11.1.5 (III) South African Carbohydrate based Intravenous Solutions Market 122 3.11.2 Salt and Electrolyte 123 3.11.2.1 Global Salt and Electrolyte based Intravenous Solutions Market 123 Exhibit 63. Salt and Electrolytes Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 124 Exhibit 64. Salt and Electrolytes Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe ,Asia-Pacific and Rest of World 125 3.11.2.2 North America Salt and Electrolyte based Intravenous Solutions Market 126 Exhibit 65. Salt and Electrolyte based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 126 Exhibit 66. Salt and Electrolyte based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 127 3.11.2.2 (I) US Salt and Electrolyte based Intravenous Solutions Market 127 3.11.2.2 (II) Canadian Salt and Electrolyte based Intravenous Solutions Market 127 3.11.2.3 European Salt and Electrolyte based Intravenous Solutions Market 128 Exhibit 67. Salt and Electrolyte based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 128 Exhibit 68. Salt and Electrolyte based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 129 3.11.2.3 (I) German Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (II) French Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (III) UK Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (IV) Swiss Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.3 (V) Russian Salt and Electrolyte based Intravenous Solutions Market 129 3.11.2.4 Asia-Pacific Salt and Electrolyte based Intravenous Solutions Market 130 Exhibit 69. Salt and Electrolyte based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 130 Exhibit 70. Salt and Electrolyte based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 131 3.11.2.4 (I) Japanese Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (II) Chinese Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (III) Indian Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (IV) Australian Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.4 (V) South Korean Salt and Electrolyte based Intravenous Solutions Market 131 3.11.2.5 Rest of World Salt and Electrolyte based Intravenous Solutions Market 132 Exhibit 71. Salt and Electrolyte based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 132 Exhibit 72. Salt and Electrolyte based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 133 3.11.2.5 (II) Brazilian Salt and Electrolyte based Intravenous Solutions Market 133 3.11.2.5 (I) Israeli Salt and Electrolyte based Intravenous Solutions Market 133 3.11.2.5 (III) South African Salt and Electrolyte based Intravenous Solutions Market 133 3.11.3 Mineral and Vitamin 134 3.11.3.1 Global Mineral and Vitamin based Intravenous Solutions Market 134 Exhibit 73. Mineral and Vitamin based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 134 Exhibit 74. Mineral and Vitamin based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 135 3.11.3.2 North America Mineral and Vitamin based Intravenous Solutions Market 136 Exhibit 75. Mineral and Vitamin based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 136 Exhibit 76. Mineral and Vitamin based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 137 3.11.3.2 (I) US Mineral and Vitamin based Intravenous Solutions Market 137 3.11.3.2 (II) Canadian Mineral and Vitamin based Intravenous Solutions Market 137 3.11.3.3 European Mineral and Vitamin based Intravenous Solutions Market 138 Exhibit 77. Mineral and Vitamin based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 138 Exhibit 78. Mineral and Vitamin based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 139 3.11.3.3 (I) German Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (II) French Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (III) UK Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (IV) Swiss Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.3 (V) Russian Mineral and Vitamin based Intravenous Solutions Market 139 3.11.3.4 Asia-Pacific Mineral and Vitamin based Intravenous Solutions Market 140 Exhibit 79. Mineral and Vitamin based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 140 Exhibit 80. Mineral and Vitamin based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 141 3.11.3.4 (I) Japanese Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (II) Chinese Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (III) Indian Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (IV) Australian Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.4 (V) South Korean Mineral and Vitamin based Intravenous Solutions Market 141 3.11.3.5 Rest of World Mineral and Vitamin based Intravenous Solutions Market 142 Exhibit 81. Mineral and Vitamin based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 142 Exhibit 82. Mineral and Vitamin based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 143 3.11.3.5 (II) Brazilian Mineral and Vitamin based Intravenous Solutions Market 143 3.11.3.5 (I) Israeli Mineral and Vitamin based Intravenous Solutions Market 143 3.11.3.5 (III) South African Mineral and Vitamin based Intravenous Solutions Market 143 3.11.4 Amino-Acid 144 3.11.4.1 Global Amino-Acid based Intravenous Solutions Market 144 Exhibit 83. Amino-Acid based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 145 Exhibit 84. Amino-Acid based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 146 3.11.4.2 North America Amino-Acid based Intravenous Solutions Market 147 Exhibit 85. Amino-Acid based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 147 Exhibit 86. Amino-Acid based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 148 3.11.4.2 (I) US Amino-Acid based Intravenous Solutions Market 148 3.11.4.2 (II) Canadian Amino-Acid based Intravenous Solutions Market 148 3.11.4.3 European Amino-Acid based Intravenous Solutions Market 149 Exhibit 87. Amino-Acid based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, UK, Switzerland, Russia and Rest of Europe in US$ Million 149 Exhibit 88. Amino-Acid based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 150 3.11.4.3 (I) German Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (II) French Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (III) UK Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (IV) Swiss Amino-Acid based Intravenous Solutions Market 150 3.11.4.3 (V) Russian Amino-Acid based Intravenous Solutions Market 150 3.11.4.4 Asia-Pacific Amino-Acid based Intravenous Solutions Market 151 Exhibit 89. Amino-Acid based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 151 Exhibit 90. Amino-Acid based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 152 3.11.4.4 (I) Japanese Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (II) Chinese Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (III) Indian Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (IV) Australian Amino-Acid based Intravenous Solutions Market 152 3.11.4.4 (V) South Korean Amino-Acid based Intravenous Solutions Market 152 3.11.4.5 Rest of World Amino-Acid based Intravenous Solutions Market 153 Exhibit 91. Amino-Acid based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 153 Exhibit 92. Amino-Acid based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 154 3.11.4.5 (II) Brazilian Amino-Acid based Intravenous Solutions Market 154 3.11.4.5 (I) Israeli Amino-Acid based Intravenous Solutions Market 154 3.11.4.5 (III) South African Amino-Acid based Intravenous Solutions Market 154 3.11.5 Other Nutrients 155 3.11.5.1 Global Other Nutrients based Intravenous Solutions Market 155 Exhibit 93. Other Nutrients based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million 155 Exhibit 94. Other Nutrients based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World 156 3.11.5.2 North America Other Nutrients based Intravenous Solutions Market 157 Exhibit 95. Other Nutrients based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million 157 Exhibit 96. Other Nutrients based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada 158 3.11.5.3 European Other Nutrients based Intravenous Solutions Market 159 Exhibit 97. Other Nutrients based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million 159 Exhibit 98. Other Nutrients based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe 160 3.11.5.4 Asia-Pacific Other Nutrients based Intravenous Solutions Market 161 Exhibit 99. Other Nutrients based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million 161 Exhibit 100. Other Nutrients based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific 162 3.11.5.5 Rest of World Other Nutrients based Intravenous Solutions Market 163 Exhibit 101. Other Nutrients based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million 163 Exhibit 102. Other Nutrients based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries 164 3.12 Intravenous Solutions – Market Outlook 165 4. PRODUCT TECHNOLOGY/RESEARCH 166 4.1 Introduction 166 Intravenous Solutions 166 Composition 166 Exhibit 103. Electrolyte Requirement 166 Exhibit 104. Contents for Common Fluids (mmol/litre) 167 Application 167 Exhibit 105. Fluid Requirements in Different Clinical Situations 168 Types of Intravenous Solutions 168 Large Volume Parenterals and Small Volume Parenterals 169 Exhibit 106. Fluid Comparison 169 Intravenous versus Oral Mode of Administration 170 Risks 171 Precautions 171 Fat Emulsions 171 Dextrose 172 Plasma Expanders 172 Cyclical Parenteral Nutrition (CPN) 172 Advantages of Cyclical PN Include 173 Exhibit 107. Global Consumption of Intravenous Solutions – 2013 Estimates 173 4.2 Segmentation of Intravenous Solutions 174 Segmentation by Type 174 Partial Parenteral Nutrition 174 Total Parenteral Nutrition 174 Complications 174 Complications due to Catheter Insertion 175 Metabolic Complications 175 Segmentation by Nutrients 175 Carbohydrates 175 Carbohydrates - Source of Nutrition 175 Introduction 175 Disadvantages of Over-feeding with the Carbon Source 176 Endogenous Glucose Production and Oxidation 177 Guidelines 177 Glucose/Fat Ratio 178 Salt and Elecrtolytes 178 Salt (Sodium chloride) and/or Other Electrolytes 178 Saline 178 Concentrations 179 Minerals and Vitamins 179 Minerals and Vitamins 179 Amino Acids 179 Amino Acids and/or Protein Hydrolysates 179 Dosage of Amino Acid Solutions for Intravenous Use 180 Other 181 Fat (lipid) Emulsions 181 Plasma Extenders 181 Exhibit 108. List of Agents Administered as IV Solutions or Additives 182 PACKAGING AND IDENTIFICATION LABELING OF APIs AND INTERMEDIATES 183 Source: FDA 183 General 183 Packaging Materials 183 Label Issuance and Control 183 Packaging and Labeling Operations 184 Storage and Distribution 184 Warehousing Procedures 184 Distribution Procedures 184 Specific Guidance for Apis Manufactured by Cell Culture/Fermentation 185 General 185 Cell Culture/Fermentation 186 Harvesting, Isolation and Purification 187 Viral Removal/Inactivation steps 187 Safety Assessment of Di (2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices 187 Safety Assessment of Di (2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices 188 Conclusions of the Safety Assessment 188 I V Infusion of Crystalloid Fluids and Drugs 188 Total Parenteral Nutrition (TPN) 188 Parenteral Nutrition 189 Government of India - Policy and Regulations on Drugs 189 Drug Regulation and Control: 189 Maharashtra FDA: Latest Reforms 190 Procedure for Drug Application in India 191 Import and Manufacturing Licenses and Approvals: 191 Labeling Requirements 191 Drug Price Regulation 192 History of Drug Price Regulation 192 Trends in Drug Price Control – India 193 Regulations on Patent Protection 194 Finale 195 A Summary of the Chinese Pharmaceutical Market 196 Consolidating the System – The State Drug Administration 196 Pharmaceutical Regulations 198 Pricing and Reimbursement 198 Pharmaceutical Classification 199 Registration 199 Clinical Investigation 202 Legal Reform: Intellectual Property Rights 204 Conclusion 205 Law of Drug Administration – China 205 Chapter I 205 General Provisions 205 Chapter II 205 Control over Drug Manufacturers 205 Chapter III 207 Control over Drug Distributors 207 Chapter V 208 Control over Drugs 208 Chapter VI 210 Control over Drug Packaging 210 Chapter VIII 211 Inspection of Drugs 211 Chapter X 212 Supplementary Provisions 212 Application of Knowledge and Skills Framework and its Review Procedure 213 Introduction 213 Decision to Form NHS KSF 213 Purpose of Skills Framework 213 Mode of Function 213 Overview 214 Distribution of Pharmaceutical Products: 215 4.3 Intravenous Solutions – Research Briefs 216 Intravenous Food Ingredients Leading to Liver Damage, Identified 216 International Dispute Regarding Intravenous Nutrition Administration May Have Been Resolved 216 Enteral Nutrition More Effective than TPN in Severe Acute Pancreatitis 217 Survival Period Post Hospital Discharge is Not Dependent on Intravenous Drug Administration 218 Intravenous Infusion Solution Ingredients Trigger Inflammation 218 Early Nasogastric-Enteral Nutrition for Managing Severe Acute Pancreatitis 219 V. CORPORATE DIRECTORY 220 VI. PATENTS INFORMATION 231
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
